Abstract:
Objective: This study was carried out to elicit the pathogenetic response of the drug Magnolia grandiflora in homoeopathic potencies on
apparently healthy human beings. Materials and Methods: Drug Magnolia grandiflora was proved by the Central Council for Research in
Homoeopathy (CCRH) through a double‑blind placebo‑controlled method. The study was conducted at three centres. The drug was proved
in two potencies (6C and 30C) on 48 apparently healthy volunteers who were selected after conducting pre‑trial medical examinations by
the medical specialists and routine laboratory investigations. In the first phase, volunteers were given 56 doses (4 doses per day for 14 days)
of placebo. In the next two phases, 56 doses (4 doses per day for 14 days) of each potency or placebo were consumed. Out of 48 provers,
32 were given the actual drug and 16 were given placebo. The symptoms generated during the trial period were noted by the volunteers and
elaborated by the proving masters. The data obtained from all the three centres were compiled at the Proving‑Cum‑Data Processing Cell at
CCRH headquarters after decoding. Results: Out of the 32 provers who were on the actual drug trial, 21 manifested symptoms. The drug was
able to produce symptoms in each potency in most of the parts of the body. Conclusion: New and proved pathogenetic responses elicited
during the proving trial expand the scope of use of the drug Magnolia grandiflora and will benefit the research scholars and clinicians. These
symptoms will carry more value when verified clinically.
